Purpose We hypothesized that intermittent anticoagulation based on daily rhythm monitoring using the novel oral anticoagulants (NOACs) is feasible and safe among patients with paroxysmal atrial fibrillation (AF). Methods Patients with paroxysmal AF and ≥1 risk factors for stroke were randomized to either intermittent or continuous anticoagulation. Those in the intermittent group were instructed to transmit a daily ECG using an iPhone-based rhythm monitoring device. If AF was detected, patients received one of the NOACs for 48 h-1 week. Patients who failed to transmit an ECG for three consecutive days or more than 7 days total were crossed over to continuous anticoagulation. Patients in the continuous group received one of the NOACs. Results Fifty-eight patients were randomized to either intermittent (n = 29) or continuous anticoagulation (n = 29). Over a median follow-up of 20 months, 20 patients in the intermittent group failed to submit a daily ECG at least once (median three failed submissions). Four patients (14 %) crossed over to continuous anticoagulation due to failure to submit an ECG for three consecutive days. One stroke (continuous group) occurred during the study. Major bleeding occurred in two patients in the continuous and one patient in the intermittent group, after crossing over to continuous anticoagulation. In a prespecified per-protocol analysis, gastrointestinal bleeding was more frequent in the continuous group (16 vs. 0 %; p = 0.047). Conclusions Intermittent anticoagulation based on daily rhythm monitoring is feasible and may decrease bleeding in low-risk patients with paroxysmal AF. A larger trial, adequately powered to detect clinical outcomes, is warranted.
Introduction
Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia and is associated with increased cardiovascular morbidity and mortality [1, 2] . Anticoagulation with either warfarin or one of the novel oral anticoagulants (NOACs) is indicated for patients with AF with prior stroke; transient ischemic attack; or a congestive heart failure/left ventricular dysfunction, hypertension, age ≥75 [doubled], and stroke [doubled]-vascular disease, age 65-74, and sex category [female] (CHA 2 DS 2 -VASc) score of 2 or greater [3] . Multiple randomized studies and meta-analyses have shown that the NOACs decrease thromboembolic events and mortality, compared to warfarin [4] [5] [6] [7] [8] . Nonetheless, the bleeding risk associated with the NOACs is not negligible, with rates of major bleeding for dabigatran and rivaroxaban being similar to those seen with warfarin [5, 7] . In addition, these agents are associated with increased risk of gastrointestinal bleeding [8, 9] . As such, the risk of thromboembolism should be balanced against the risk of bleeding [3] . As patient preferences regarding the relative importance of preventing strokes and avoiding bleeding vary widely [10] , alternative approaches to long-term anticoagulation need to be considered.
Thrombus formation in the left atrium is thought to represent the main source of thromboembolic events in patients with AF [11] . Consistent with recent evidence suggesting that paroxysmal AF may be associated with a lower incidence of stroke compared to persistent AF [12] [13] [14] [15] , we hypothesized that in a selected group of patients with paroxysmal AF and a low risk of stroke, maintaining therapeutic anticoagulation only during episodes of AF (either symptomatic or asymptomatic) may provide the benefits of continuous anticoagulation in terms of stroke prevention, while decreasing the risk of bleeding complications. This approach requires an oral anticoagulant with rapid onset of anticoagulation (a NOAC), as well as remote rhythm monitoring. Although implantable devices offer continuous rhythm monitoring, their use is limited to patients with an indication for a dual-chamber pacemaker or defibrillator. Insertable cardiac monitors represent an emerging alternative approach for continuous monitoring, and although they can accurately detect AF [16] , they may be associated with higher risk of complications [17] and increased cost, thus decreasing patient acceptability. A new, inexpensive, and convenient iPhone-based rhythm monitoring device is currently available and can detect AF with high sensitivity and specificity [18] . In this pilot study, we tested the feasibility and preliminary safety of intermittent anticoagulation based on daily iPhone-based rhythm monitoring among patients with paroxysmal AF and one or more additional risk factors for stroke.
Methods
This was a prospective open-label randomized controlled pilot study. Patients with paroxysmal AF, documented by ECG, implantable device electrogram, or Holter monitor, within 6 months of randomization on two separate occasions, at least 1 day apart, were eligible for enrollment. In addition, patients were required to have at least one additional risk factor for stroke, including left ventricular ejection fraction ≤40 % or symptomatic heart failure, age ≥75, diabetes, hypertension, or age ≥65 with documented coronary artery disease. Patients were excluded if they had any of the following: prior stroke or transient ischemic attack, prosthetic valve or hemodynamically significant valve disease, reversible causes of AF, severe renal impairment (estimated creatinine clearance 30 mL/min or less), active liver disease, anemia (hemoglobin less than 10 g/dL) or thrombocytopenia (platelets less than 100 × 10 9 /L), and pregnancy or nursing. Patients were enrolled from November 2013 until June 2015. In December 2014, after the new guidelines for AF were published [3] , the Data Safety Monitoring Board recommended that the protocol be amended to include only patients with a CHA 2 DS 2 -VASc score of 1, to comply with the new guidelines. Women with one additional risk factor could be included in the study. Patients who were randomized to intermittent anticoagulation who subsequently met a new exclusion criterion were informed of the new guidelines and were crossed over to the continuous anticoagulation arm unless the patient refused to do so, in which case, the patient remained in the intermittent anticoagulation group and continued to be followed for clinical events as per the study protocol.
Following enrollment, patients were randomly assigned in a 1:1 ratio to either intermittent or continuous anticoagulation. Patients in the continuous anticoagulation group received one of the NOACs, with the choice of the NOAC left to the discretion of the referring physician. Patients who were previously on warfarin were started on one of the NOACs after their INR fell to about 2.0 [3] . Those in the intermittent anticoagulation group were provided with an iPhone-based rhythm monitoring device and were instructed to transmit a daily 30-s ECG rhythm strip at approximately the same time of the day, as well as when experiencing symptoms of AF. If AF was detected, as confirmed by one of the investigators, the patients were instructed to start anticoagulation immediately. By doing so, patients started anticoagulation within 24 h after the onset of AF. To increase compliance of the participants with daily rhythm monitoring, an automatic daily reminder was programmed through their iPhones. In addition, patients who did not transmit their rhythm for two consecutive days received a reminder call from one of the investigators. When AF was detected based on rhythm monitoring, patients received anticoagulation for 48 h to 1 week, according to a prespecified algorithm, depending on the duration of the AF episode, to account for atrial stunning [19] [20] [21] . Specifically, for episodes lasting less than 48 h, anticoagulation was continued for 48 h, while for episodes lasting 2 days to 1 week, anticoagulation was continued for 1 week (Fig. 1) . Patients who failed to transmit an ECG for three consecutive days, despite measures to ensure compliance, or failed to transmit an ECG for a total of more than 7 days regardless of time span were crossed over to the continuous anticoagulation arm. Patients who developed persistent AF, defined as AF duration greater than 7 days or requiring cardioversion [3] , were also crossed over to the continuous anticoagulation arm. The percentage of participants who crossed over to continuous anticoagulation was used as a measure of adherence to the protocol of daily rhythm monitoring.
The primary feasibility endpoint of the study was adherence to the prespecified protocol of intermittent anticoagulation. Primary efficacy and safety endpoints included stroke or systemic embolism and major bleeding, respectively. Secondary endpoints included death, the composite of death or stroke or systemic embolism, and gastrointestinal bleeding and the composite of major or gastrointestinal bleeding. Major bleeding was defined according to the ISTH criteria as clinically overt bleeding accompanied by a decrease in the hemoglobin level of at least 2 g/dL or transfusion of at least 2 units of packed red cells, occurring at a critical site or resulting in death or permanent disability. All endpoints were adjudicated by an independent committee, the members of which were not be involved in patient care and were unaware of the treatment assignments. The Institutional Review Board at the University of Oklahoma Health Sciences Center approved the study prior to its initiation, and informed consent was obtained from each patient.
Statistical analysis
Continuous data are presented as mean ± standard deviation or median and interquartile range (IQR), as appropriate. Categorical data are presented as percentages. Means were compared using a two-sample t test. Proportions were compared using a chi-square test and Fisher's exact test, when more than 25 % of expected frequency counts were less than five or any zero counts were observed in a category or a Cochran-Armitage trend test for ordered categories. The time-to-major bleeding and time-to-gastrointestinal bleeding distributions were estimated for each therapy group using the Kaplan-Meier method, and 18-month event rates for each group were derived. The time-to-thromboembolic event distributions and survival distributions were estimated in a similar manner. Timeto-event distributions were compared between the two groups using a log-rank test. The cumulative incidence of crossing over from intermittent to continuous therapy due to poor adherence was estimated while accounting for death and crossing over due to AF as competing events [22] . Analyses reflect an intent-to-treat paradigm in which all data were analyzed according to randomized treatment assignment; per-protocol analyses were also performed, where data were analyzed up to the point in time when the patient on intermittent therapy crossed over to continuous therapy. A two-stage monitoring approach was used to monitor major cardiovascular event rates, in each arm separately, as a guide to identify unacceptable levels of risk using a Simon two-stage design [23] . The sample size of this pilot study was driven by feasibility considerations with the intent to estimate protocol adherence and to derive preliminary estimates of stroke, death, and bleeding event rates. Statistical significance was declared at p < 0.05.
Results
Of 88 potentially eligible patients screened, 58 patients were enrolled in the study (Fig. 2) . Among the 58 patients, 29 (50 %) were randomized to intermittent anticoagulation and 29 (50 %) were randomized to continuous anticoagulation. The baseline characteristics of the patients were balanced between the two groups (Table 1 ). In the intermittent group, 19 (65 %) patients were prescribed apixaban, 8 (28 %) were prescribed rivaroxaban, and 2 (7 %) were prescribed dabigatran. In the continuous group, apixaban, rivaroxaban, and dabigatran were prescribed in 20 (69 %), 7 (24 %), and 2 (7 %) patients, respectively. Sixteen (55 %) and 14 (48 %) patients in the intermittent and the continuous group, respectively, were taking an antiarrhythmic drug at the time of enrollment, including amiodarone (2 intermittent and 4 continuous) and dronedarone (1 intermittent). Five (18 %) patients in each group had undergone a catheter ablation for AF at least 6 months prior to enrollment.
During a median follow-up of 20 months (IQR 13 to 22 months), among the 29 patients randomized to intermittent anticoagulation, 4 (14 %) crossed over to continuous anticoagulation due to failure to submit rhythm strips. Six additional patients crossed over due to development of persistent AF. Following the Data and Safety Board's recommendation to change eligibility criteria, no patients agreed to be crossed over from intermittent to continuous therapy. The cumulative incidence of crossing over due to failure to submit 13.3 ± 1.9 13.6 ± 1.7 0.51 a Patients could select multiple agents, and therefore, the counts do not sum to the total number of patients the rhythm strips for three consecutive days is summarized in Fig. 3a . The time-to-crossover distribution for all patients assigned to intermittent therapy, regardless of the reason for crossing over, is summarized in Fig. 3b . Among the 29 patients assigned to the intermittent arm, 20 patients failed to submit rhythm strips a total of 81 times over 410 personmonths of follow-up completed prior to crossing over to the continuous therapy arm. The resulting rate is 1 failed submission per 5 person-months of follow-up. Among the 29 patients, the number of failed submissions ranged from 0 to 7 with a median value of 3 failed submissions (IQR 0 to 5 submissions). A total of 160 AF episodes were detected through the submitted rhythm strips in 18 of 29 patients in the intermittent arm during 478 person-months of follow-up, resulting in an AF rate of approximately 1 episode per 2.7 person-months of follow-up. Among the 29 patients assigned to the intermittent group, the number of AF episodes ranged from 0 to 49 with a median value of 1 episode (IQR 0 to 5 episodes). Among the 18 patients experiencing at least one episode, the number of AF episodes ranged from 1 to 49 with a median value of 4 episodes (IQR 1 to 16 ). Of the 160 detected episodes, 138 (86 %) lasted <48 h and 16 (10 %) episodes lasted 48 h-1 week (12 lasted <72 h and all lasted <96 h). Six episodes (one in each patient) lasted >1 week and resulted in crossing over to the continuous arm due to development of persistent AF, according to study protocol. Of those, four patients were cardioverted to sinus rhythm and all six remained in the continuous group for the remainder of the study. In all patients, anticoagulation was started within 1 h of confirmation of the presence of AF by one of the investigators. In five patients in the intermittent group, the presence of implantable devices allowed us to compare their true AF burden, with the AF detection rate obtained from noninvasive daily rhythm monitoring. One patient had a lot of short episodes (approximately 25 episodes per month, corresponding to high AF density [24] ), many of which were not picked up by daily rhythm monitoring, which provided an AF rate of approximately 1 episode per month. In the rest of the patients with infrequent, more prolonged episodes, the AF burden obtained by the two methods was comparable, ranging from 0 to 1 episode per 1.3 months by continuous monitoring through the implantable device vs. 0 to 1 episode per 1.8 months by daily rhythm monitoring. Concordance and discordance rates between iPhone-and device-based AF detection are summarized in Table 2 . Fig. 3 Cumulative incidence of crossover to continuous anticoagulation due to nonadherence (a) and time-to-crossover distribution regardless of the reason for crossover (b) in patients initially assigned to intermittent anticoagulation Three patients withdrew consent (one in the intermittent and two in the continuous group), and one patient was lost to follow-up (continuous group) during the course of the study (Fig. 1) . Three noncardiac deaths (one in the continuous and two in the intermittent group), one cardiovascular death (cardiogenic shock in the intermittent group), and one stroke (continuous group) occurred during the study. No strokes occurred in the intermittent anticoagulation group. Of note, the patient who had a stroke was found to have significant ipsilateral carotid artery stenosis and underwent carotid artery stenting. Under the intent-to-treat analysis, the rates of stroke or systemic embolism did not differ significantly between the intervention groups (p = 0.32) (Fig. 4a) . Likewise, the rates of death or stroke (composite endpoint) were not significantly different between the groups (p = 0.65) (Fig. 4b) .
Major bleeding occurred in two patients in the continuous group and one patient in the intermittent group, after crossing over to continuous anticoagulation. All major bleeding events were due to gastrointestinal bleeding. There was no difference in the major bleeding-free probability between the two groups (p = 0.61 in the intent-to-treat analysis and p = 0.18 in the perprotocol analysis; Fig. 5a ) Seven gastrointestinal bleeding events occurred in five patients (four in the continuous group and one in the intermittent group after crossing over to continuous group). In the intent-to-treat analysis, the 18-month estimated gastrointestinal bleeding-free probability was 96 % (95 % CI 76 to 99 %) in the intermittent group and 84 % (95 % CI 63 to 94 %) in the continuous group (p = 0.17). In a prespecified per-protocol analysis, gastrointestinal bleeding was more frequent in the continuous group compared to the intermittent group (18-month estimated gastrointestinal bleeding-free probability 84 % [95 % CI 63 to 94 %] vs. 100 %, respectively; p = 0.047) (Fig. 5b) .
Discussion
In this study, a strategy of intermittent anticoagulation only during paroxysmal episodes of AF, based on daily rhythm monitoring using an iPhone-based device, was feasible among patients with paroxysmal AF and relatively low risk of stroke. Our study confirms the results of the recently published REACT.COM study, which showed that targeted anticoagulation based on rhythm monitoring using an insertable cardiac monitor is feasible [25] and expands them in the sense that it is the first study to use a noninvasive monitoring device to guide anticoagulation therapy. Patients who may mostly benefit from this strategy include those with low risk of thromboembolic events (specifically those with a CHA 2 DS 2 -VASc score of 1) and/or those with a relatively high bleeding risk, in whom the current practice is to err on the side of withholding anticoagulation. In addition, this approach may be very attractive to the small percentage of patients who would not be willing to consider any anticoagulation therapy even it was 100 % effective in preventing strokes, because of concerns of bleeding complications [10] . Such patient-tailored anticoagulation therapy for AF is supported by the current guidelines, which recommend a discussion of the risks of stroke and bleeding and the individual patient's preferences before initiating anticoagulation therapy [3] . As a result of the pilot nature of our study and small sample size, our study was not powered to detect clinically important differences of modest size in stroke or major bleeding. Nonetheless, in a prespecified per-protocol analysis, there was a significant reduction of gastrointestinal bleeding in the intermittent group, without an increase in the stroke rate. Few patients developed gastrointestinal bleeding (four in the continuous arm and none in the intermittent arm prior to crossing over), and therefore, this result must be interpreted cautiously. An increased risk of bleeding in the continuous arm is in line with recent data showing that NOACs increase gastrointestinal bleeding rates [8, 9] . In essence, the concept of intermittent anticoagulation attempts to decrease the risk of bleeding while maintaining stroke prevention. In other words, it aims to maximize the risk/benefit ratio of anticoagulation. Our study by no means implies that this is the case, but it does prove that the approach is feasible and provides the basis for the design of a larger trial, adequately powered to detect clinically significant outcomes. Adherence to the protocol of intermittent anticoagulation may represent a challenge, given that daily monitoring is required, but it is an essential component of this approach. The process of daily rhythm monitoring using a smartphone-based device to guide anticoagulation therapy requires adequate patient motivation; thus, patient selection is extremely important. It has been shown that patients' attitudes toward anticoagulation vary widely, with some patients refusing anticoagulation because of the increased bleeding risk [10] . Thus, some patients with AF would be highly motivated and would be willing to adhere to a protocol of daily rhythm monitoring, in order to avoid continuous anticoagulation. In a nonselected group of patients, such as ours, adherence to the protocol of daily rhythm monitoring was very good, with only 4 of 29 (14 %) crossing over to continuous anticoagulation due to nonadherence to the protocol of daily rhythm monitoring and only 1 failed submission per 5 person-months of followup. In addition, as shown in Fig. 3a , those who did not adhere to the protocol and had to be crossed over to the continuous arm did so early in the study, and no late crossovers were observed, suggesting that nonadherence was due to intrinsic patient characteristics (making them prone to noncompliance to any measure), rather than the burden of the daily rhythm monitoring process. A run-in phase would have likely reduced the incidence of nonadherence. On the other hand, daily physician interpretation of the transmitted ECG, the workflow, and the information technology associated with this approach is not trivial. Thus, improvement in the AF detection algorithm to achieve almost 100 % sensitivity is imperative for the success of future studies using this approach. This will allow the investigators to review only those recordings that are read by the device as AF, in order to decrease the burden of having to review each and every transmitted recording.
Although the association between AF and stroke has been established in multiple epidemiological studies, the exact mechanism of stroke remains poorly understood [11] . Multiple studies have shown a correlation between thromboembolic risk and asymptomatic AF episodes of variable duration detected through implantable devices [26] [27] [28] [29] , even though a temporal association of an incident stroke with an antecedent AF episode was frequently absent in the aforementioned studies [30, 31] . This apparent discrepancy can be explained in part by the understanding that thrombus formation during an AF episode and thrombus embolization causing a stroke may be temporally distinct events. The former may occur during an AF episode, which is associated with prothrombotic activation, endothelial dysfunction, and inflammation [32] , while the thrombus may remain stable for months before it finally embolizes [33] . In addition, it has been proposed that AF burden may play a significant role in patients with low risk of stroke (low CHA 2 DS 2 -VASc score), whereas in patients with a high risk of stroke, the influence of AF burden on stroke diminishes [34, 35] . This notion is consistent with recent evidence indicating that paroxysmal AF may be associated with a lower stroke risk compared to persistent [12] [13] [14] [15] . Moreover, alternative mechanisms beyond AF, including other potential sources of cardiac emboli, as well as atherothrombotic mechanisms, may be the actual cause of stroke in a significant proportion of patients with AF [36] . Importantly, the proportion of alternative mechanisms of stroke increased with increasing CHA 2 DS 2 -VASc score [36] . Although the optimal duration of AF that merits anticoagulation has not been established, the available evidence suggests that recurrent episodes of AF lasting more than a few hours do carry an increased risk of stroke, with the patients' other thromboembolic risk factors acting as modifiers of this risk [34, 37] .
In our study, the AF burden was relatively low. The AF detection rate was approximately one episode per 3 personmonths of follow-up, and 11 patients had no AF episodes detected. Although these numbers likely underestimate the patients' true AF burden, these data are consistent with the results of studies in patients with symptomatic paroxysmal AF who also had an indication for a standard dual-chamber pacemaker, which showed that most patients have no more than a few episodes per month, while a significant number of patients do not experience any episode during short-term follow-up [38, 39] . Data from a small subgroup of patients with implantable devices support the notion that in the presence of low AF density (infrequent episodes), the relative benefit of continuous monitoring over intermittent monitoring in representing the true AF burden is attenuated [24] .
The recently published REACT.COM study explored the concept of intermittent anticoagulation in 59 patients with paroxysmal or persistent AF who had an insertable loop recorder. NOACs were initiated for 30 days for any AF episode lasting ≥1 h based on daily loop recorder transmissions [25] . This study showed a 98 % compliance with daily transmissions and a 94 % reduction in anticoagulation utilization with the use of targeted rhythm-guided anticoagulation therapy, establishing the feasibility of this approach. Consistent with prior studies including patients with implantable devices [38, 39] , REACT.COM demonstrated that long periods of sinus rhythm in patients with paroxysmal AF are not uncommon, forming the basis for intermittent anticoagulation to decrease exposure to anticoagulants. Importantly, recent evidence suggests that these patients with rare, short-lived episodes (low AF burden) may have a lower risk of stroke compared with those with long frequent episodes (high AF burden), especially in the presence of only mild comorbidities [37] .
Our findings contrast with the results of a recent randomized trial of remote monitoring to guide initiation and discontinuation of anticoagulation in patients with previously implanted defibrillators or cardiac desynchronization devices (IMPACT study), which failed to show a positive result [40] . There are significant differences between the two studies in terms of study design and population included, which might explain the contrasting results. In the IMPACT study, continuation of AF for 24 to 48 h (for CHADS 2 scores 3-4 and 1-2, respectively) was required before initiation of anticoagulation, whereas, in our study, anticoagulation was initiated immediately after AF was identified. In addition, the anticoagulant used in the majority of the patients (>80 %) in the IMPACT study was warfarin, which, in contrast to the NOACs used in our study, requires a few days to reach therapeutic levels. Finally, the patients included in the IMPACT study had, on average, a higher stroke risk (median CHA 2 DS 2 -VASc score of 4) compared to our patient population, supporting the notion that the temporal dissociation of AF with stroke may have resulted from more advanced atrial myopathy in this patient population with heart failure.
Limitations
The small sample size of this pilot study does not allow definitive conclusions to be drawn. However, the study was primarily designed to show feasibility of intermittent anticoagulation and derive preliminary estimates for power calculations for a larger, more definitive study. Nonetheless, these results suggest that this approach may decrease the rates of bleeding complications associated with the use of NOACs. It should be noted that intermittent anticoagulation would work only if the major source of thromboembolism is related to AF, i.e., in the absence of significant comorbidities [37] . The protocol of anticoagulation in the intermittent group was based on extrapolations from previous studies examining the duration of atrial stunning in relation to the duration of the AF episode [19] [20] [21] . Specifically, these demonstrated that recovery of the left atrial mechanical function occurred within 3 min for AF episodes lasting 15 min, within 24 h for AF episodes lasting <2 weeks and within 1 week for AF episodes lasting 2-6 weeks. A systematic study of the optimal intermittent anticoagulation protocol was out of the scope of this pilot study. A more conservative approach would be to provide anticoagulation for a longer period of time (e.g., 3-4 weeks), irrespective of the duration of the AF episode. However, this approach would result in a longer exposure to anticoagulants, thus negating the primary benefit of intermittent anticoagulation, which is to prevent bleeding. Although more frequent rhythm monitoring (e.g., twice or thrice a day) would have resulted in identification of shorter episodes of AF (less than 12 and 8 h, respectively), adherence to the monitoring protocol may have been significantly reduced [41] . Therefore, we opted to simplify the protocol to include once-daily monitoring rather than multiple times a day, in order to maximize adherence. Importantly, the protocol was designed to ensure initiation of anticoagulation within 24 h of AF onset, which is well within the 48-h window currently accepted as the minimum duration required for thrombus formation [3] . Our study underestimated the true AF burden of these patients due to the intermittent nature of AF monitoring, corroborated by the disparity between iPhone-based and device-based AF detections in patients with implantable devices, especially in the presence of frequent, short episodes. Continuous monitoring through an implantable device is superior to intermittent noninvasive monitoring in defining the AF burden [24] . An alternative approach would be to guide anticoagulation therapy using an insertable cardiac monitor [25] . However, rhythm monitoring through an inexpensive and convenient iPhone-based device greatly expands the generalizability and decreases the cost of this approach.
Conclusions
These data suggest that intermittent anticoagulation using an iPhone-based rhythm monitoring device is feasible and may be associated with decreased bleeding risk without apparent increase in stroke in low-risk patients with paroxysmal AF. Further investigation with a larger trial, adequately powered to establish noninferiority of intermittent anticoagulation compared to continuous anticoagulation in reducing the risk of stroke or death and superiority in reducing the risk of major bleeding, is warranted.
